J
Jingjing Zhou
Researcher at Capital Medical University
Publications - 31
Citations - 317
Jingjing Zhou is an academic researcher from Capital Medical University. The author has contributed to research in topics: Major depressive disorder & Medicine. The author has an hindex of 4, co-authored 14 publications receiving 77 citations.
Papers
More filters
Journal ArticleDOI
Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders.
Jian Yang,Peng Zheng,Yifan Li,Jing Wu,Xunmin Tan,Jingjing Zhou,Zuoli Sun,Xu Chen,Guofu Zhang,Hanping Zhang,Yu Huang,Tingjia Chai,Jiajia Duan,Weiwei Liang,Bangmin Yin,Jianbo Lai,Tingting Huang,Yanli Du,Peifen Zhang,Jiajun Jiang,Caixi Xi,Lingling Wu,Jing Lu,Tingting Mou,Yi Xu,Seth W. Perry,Seth W. Perry,Ma-Li Wong,Ma-Li Wong,Julio Licinio,Julio Licinio,Shaohua Hu,Gang Wang,Peng Xie +33 more
TL;DR: Using whole-genome shotgun metagenomic and untargeted metabolomic methods, a combinatorial marker panel is identified that robustly discriminated MDD from HC individuals in both the discovery and validation sets, providing a deep insight into understanding of the roles of disturbed gut ecosystem in MDD.
Journal ArticleDOI
Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression.
Peng Zheng,Jian Yang,Yifan Li,Jing Wu,Weiwei Liang,Bangmin Yin,Xunmin Tan,Yu Huang,Tingjia Chai,Hanping Zhang,Jiajia Duan,Jingjing Zhou,Zuoli Sun,Xu Chen,Subhi Marwari,Jianbo Lai,Tingting Huang,Yanli Du,Peifen Zhang,Seth W. Perry,Ma-Li Wong,Julio Licinio,Shaohua Hu,Peng Xie,Gang Wang +24 more
TL;DR: In this article, using 16S ribosomal RNA (rRNA) gene sequencing, the microbial compositions of 165 subjects with MDD are compared with 217 BD, and 217 healthy controls (HCs).
Journal ArticleDOI
Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial.
Le Xiao,Xuequan Zhu,Amy Gillespie,Yuan Feng,Jingjing Zhou,Xu Chen,Yuanyuan Gao,Xueyi Wang,Xiancang Ma,Chengge Gao,Yunshi Xie,Xiaoping Pan,Yan Bai,Xiufeng Xu,Gang Wang,Runsen Chen +15 more
TL;DR: The results of this trial do not support a recommendation to routinely offer additional treatment or a switch in treatment strategies for MDD patients who do not show early improvement after 2 weeks of antidepressant treatment.
Journal ArticleDOI
Does early and late life depression differ in residual symptoms, functioning and quality of life among the first-episode major depressive patients
Le Xiao,Jingjing Zhou,Yuan Feng,Xuequan Zhu,Wenyuan Wu,Yongdong Hu,Yajuan Niu,Jian Hu,Xueyi Wang,Chengge Gao,Ning Zhang,Yiru Fang,Tiebang Liu,Fu-Jun Jia,Lei Feng,Gang Wang +15 more
TL;DR: In first major depressive episode, early age was strongly associated with depressive severity and functional impairment after responding to antidepressant treatment.
Journal ArticleDOI
Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
TL;DR: This study will provide the first insight regarding the rapid antidepressant efficacy and tolerability of an intramuscular scopolamine add-on to the usual treatment in Chinese MDD patients, and will accelerate early antidepressant efficacy.